Question explored with the scientific record
What is the best treatment for migraine
There is no single best migraine drug. The honest answer is that acute relief is well proven for triptans and gepants, and prevention is well proven for CGRP antibodies and botulinum toxin, but the evidence here is short-term and mostly industry-run.
For an attack, triptans have the strongest numbers. Eletriptan 40 mg beat sumatriptan 100 mg on pain-free response at 2 hours, 35% versus 25% [3]. Sumatriptan injection gave relief in 70% versus 35% on placebo [2]. Gepants are the newer option: rimegepant produced 2-hour pain freedom in about 19 to 21% of patients [4], and ubrogepant in 20% versus 12% on placebo [4]. Gepants avoid the vasoconstriction that limits triptans [1].
For prevention, CGRP antibodies work. In chronic migraine they roughly doubled the 50% responder rate versus placebo [7], and fremanezumab cut monthly migraine days by about 2.8 [5]. Botulinum toxin reduced headache days by 9.0 versus 6.7 on placebo in chronic migraine [8].
| Option | Main result | Comparator |
|---|---|---|
| Eletriptan 40 mg | 35% pain-free at 2h | 25% sumatriptan [3] |
| Sumatriptan injection | 70% relief | 35% placebo [2] |
| Ubrogepant | 20% pain-free at 2h | 12% placebo [4] |
| CGRP antibody (chronic) | ~2x 50% responder rate | placebo [7] |
| Botulinum toxin | -9.0 headache days | -6.7 placebo [8] |
These trials are short. Most run 12 to 24 weeks, so long-term safety is not established here [5][6]. Several are open-label or industry-adjacent, and the reviews inherit publication bias. Magnesium helped mainly in migraine with aura, not overall [2].
My call: start with a triptan or gepant for attacks and a CGRP antibody or botulinum toxin for frequent attacks, matched to your history. Confidence: moderate for short-term benefit, low for long-term safety.
Sources used 8
-
Selective seratonin 1F (5-HT1F) receptor agonist LY334370 for acute migraine: a randomised controlled trial
The study investigates the efficacy of LY334370, a selective serotonin 1F receptor agonist, in treating acute migraine, demonstrating significant improvements in migraine relief compared to placebo without the vasoconstrictive side effects associated with traditional triptans.
DOI: 10.1016/s0140-6736(01)06347-4 -
Rescue Therapy for Acute Migraine, Part 1: Triptans, Dihydroergotamine, and Magnesium
This article is a comprehensive narrative review (Part 1 of a 3-part series) evaluating published studies of rescue therapy for acute migraine administered by health-care providers in emergency department, urgent care, and headache clinic settings, focusing on triptans, dihydroe…
DOI: 10.1111/j.1526-4610.2011.02062.x -
The 40‐mg dose of eletriptan: comparative efficacy and tolerability versus sumatriptan 100 mg
A pooled head-to-head comparison of eletriptan 40 mg versus sumatriptan 100 mg in acute migraine treatment across three randomized trials shows eletriptan provides higher efficacy across multiple outcomes (2-h headache response, pain-free, and sustained responses) with comparabl…
DOI: 10.1046/j.1351-5101.2003.00730.x -
Role of calcitonin gene-related peptide (CGRP) receptor antagonist in acute and preventive treatment of migraine.
This narrative review of gepants (CGRP receptor antagonists) reports that rimegepant, ubrogepant, and atogepant are effective versus placebo for acute and preventive migraine treatment with a favorable safety profile.
DOI: 10.56782/pps.206 -
CGRP, a target for preventive therapy in migraine and cluster headache: Systematic review of clinical data
Clinical data from phase II and III trials of four anti-CGRP monoclonal antibodies collectively show a positive preventive effect in episodic and chronic migraine with acceptable short-term safety.
DOI: 10.1177/0333102417741297 -
Efficacy and Safety of Fremanezumab in the Preventive Treatment of Migraine: A Systematic Review of Randomized Clinical Trials
This systematic review found that fremanezumab significantly reduced migraine frequency and produced clinically meaningful response rates, with a low rate of treatment-unrelated serious adverse events, though trials had short follow-up and homogeneous populations.
DOI: 10.46979/rbn.v61i4.69673 -
CGRP monoclonal antibody for preventive treatment of chronic migraine: An update of meta‐analysis
CGRP monoclonal antibodies improved 50% and 75% responder rates versus placebo in chronic migraine, with injection site discomfort as the main adverse event.
DOI: 10.1002/brb3.1215 -
OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial
The PREEMPT 2 study demonstrates that onabotulinumtoxinA is effective and safe for the prophylaxis of chronic migraine in adults, significantly reducing headache days compared to placebo.
DOI: 10.1177/0333102410364677